ES2182983T3 - Formulaciones para la liberacion de peptidos. - Google Patents

Formulaciones para la liberacion de peptidos.

Info

Publication number
ES2182983T3
ES2182983T3 ES96917292T ES96917292T ES2182983T3 ES 2182983 T3 ES2182983 T3 ES 2182983T3 ES 96917292 T ES96917292 T ES 96917292T ES 96917292 T ES96917292 T ES 96917292T ES 2182983 T3 ES2182983 T3 ES 2182983T3
Authority
ES
Spain
Prior art keywords
formulation
deslorelin
peptides
formulations
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96917292T
Other languages
English (en)
Spanish (es)
Inventor
John Desmond Walsh
Timothy Elliot Trigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Peptech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech Ltd filed Critical Peptech Ltd
Application granted granted Critical
Publication of ES2182983T3 publication Critical patent/ES2182983T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ES96917292T 1995-06-20 1996-06-20 Formulaciones para la liberacion de peptidos. Expired - Lifetime ES2182983T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN3667A AUPN366795A0 (en) 1995-06-20 1995-06-20 Formulation for preventing reproductive function

Publications (1)

Publication Number Publication Date
ES2182983T3 true ES2182983T3 (es) 2003-03-16

Family

ID=3788008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96917292T Expired - Lifetime ES2182983T3 (es) 1995-06-20 1996-06-20 Formulaciones para la liberacion de peptidos.

Country Status (16)

Country Link
US (2) US5925619A (enExample)
EP (1) EP0871467B1 (enExample)
JP (1) JP4016133B2 (enExample)
CN (1) CN1145496C (enExample)
AT (1) ATE223726T1 (enExample)
AU (2) AUPN366795A0 (enExample)
CA (1) CA2225796C (enExample)
DE (2) DE69623652T2 (enExample)
DK (1) DK0871467T3 (enExample)
ES (1) ES2182983T3 (enExample)
FR (1) FR08C0001I2 (enExample)
NL (1) NL300330I2 (enExample)
NZ (1) NZ309697A (enExample)
PT (1) PT871467E (enExample)
SI (1) SI0871467T1 (enExample)
WO (1) WO1997000693A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
CA2264562C (en) 1996-08-30 2012-01-03 Peptech Limited Sustained peptide-release formulation
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
US8052982B2 (en) * 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
US6211221B1 (en) * 1999-04-05 2001-04-03 Johnny W. Peterson Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
CA2552241C (en) * 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US20080254086A1 (en) * 2004-12-23 2008-10-16 Brown James E Controlled Release Compositions
KR20100059863A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 4 단독 또는 세크로핀 a와의 배합물의 용도
DE102008015104A1 (de) 2008-03-19 2009-09-24 Basf Coatings Ag Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS563846B2 (enExample) * 1972-10-12 1981-01-27
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function

Also Published As

Publication number Publication date
AU701837B2 (en) 1999-02-04
EP0871467A4 (en) 2000-07-05
NL300330I1 (nl) 2008-03-03
CN1188414A (zh) 1998-07-22
DE122008000004I1 (de) 2008-04-17
NZ309697A (en) 1999-11-29
DK0871467T3 (da) 2002-12-23
JP4016133B2 (ja) 2007-12-05
CN1145496C (zh) 2004-04-14
CA2225796A1 (en) 1997-01-09
CA2225796C (en) 2011-09-20
AUPN366795A0 (en) 1995-07-13
HK1014874A1 (en) 1999-10-08
DE122008000004I2 (de) 2009-08-06
EP0871467A1 (en) 1998-10-21
FR08C0001I1 (enExample) 2008-03-21
PT871467E (pt) 2002-12-31
JP2001521482A (ja) 2001-11-06
US5925619A (en) 1999-07-20
DE69623652T2 (de) 2003-05-28
NL300330I2 (nl) 2008-04-01
DE69623652D1 (de) 2002-10-17
FR08C0001I2 (enExample) 2009-11-20
EP0871467B1 (en) 2002-09-11
WO1997000693A1 (en) 1997-01-09
US6211152B1 (en) 2001-04-03
ATE223726T1 (de) 2002-09-15
AU5992796A (en) 1997-01-22
SI0871467T1 (en) 2003-08-31

Similar Documents

Publication Publication Date Title
FR08C0001I2 (enExample)
AU560829B2 (en) Continuous release pharmaceutical compositions
AU4718496A (en) Use of aerogels in agriculture
ES2050070B1 (es) Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
NZ283135A (en) Gel formulation for treatment of skin diseases and disinfection/disinfestation of the skin
AU7888398A (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
MX9801835A (es) Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
AU5673399A (en) Compositions and methods for treating intracellular infections
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
AU5643299A (en) Humic acid and its use in the treatment of various conditions
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
OA09771A (en) Asphodelus composition for increasing white blood cell count.
AU589254B2 (en) Slow release formulations
IT1245148B (it) Glicoproteine estratte da apparati riproduttori femminili, loro uso in dermatologia e cosmesi della pelle e delle mucose
BG51699A1 (en) Stimulating fertility agent
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
UA30723A (uk) Спосіб лікування аутоімунних захворювань
BR9810930A (pt) Composições farmacêuticas de arglabina e derivados de arglabina
GR1002955B (el) Προιοντα που προερχονται απο το φυτο κυπαρισσος και ολα τα συγγενη κωνοφορα, για χρηση στην προληψη και θεραπεια καθε τυπου υπερχοληστεριναιμιας και διαταραχης λιπιδιων, σε ανθρωπους και ζωα
UA36126A (uk) Бандаж поперековий